NanoViricides, Inc. (NYSE American: NNVC) has scheduled its Annual Shareholders Meeting for November 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. The clinical-stage company continues development of its nanoviricide platform technology designed to create broad-spectrum antiviral treatments that could address multiple viral threats simultaneously.
The company's lead drug candidate, NV-387, represents a significant advancement in antiviral therapy as it targets multiple respiratory viruses including RSV, COVID-19, influenza, and other respiratory infections, along with potential applications for MPOX and Smallpox. This broad-spectrum approach is particularly important given the increasing frequency of viral outbreaks and the limitations of current virus-specific treatments. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though specific timelines remain dependent on external collaborators.
NanoViricides' technology platform, licensed from TheraCour Pharma, Inc., enables the development of special purpose nanomaterials that can prevent viral escape mechanisms. The company holds exclusive worldwide licenses for this technology across multiple viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue fever, Ebola virus, and several coronavirus strains. Additional information about the company's technology and development programs is available at https://www.nanoviricides.com.
The company's second advanced candidate, NV-HHV-1, targets Shingles treatment, while other development programs address oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, and numerous other viral threats. This diversified pipeline demonstrates the platform technology's potential applicability across multiple viral families and disease states.
Investors can access the latest company developments through the newsroom at https://ibn.fm/NNVC, which provides ongoing updates about the company's progress. The broad licensing agreement with TheraCour covers specific targeting mechanisms for numerous viral diseases in perpetuity, providing long-term development rights for these critical therapeutic areas.
The development of broad-spectrum antiviral drugs represents a crucial advancement in pandemic preparedness and routine viral infection management. Current antiviral treatments typically target specific viruses, leaving healthcare systems vulnerable to emerging threats and requiring new drug development for each novel pathogen. NanoViricides' platform approach could potentially address this limitation by creating treatments effective against multiple related viruses.
As with all pharmaceutical development, the company acknowledges the inherent risks of drug development, including the lengthy timeline, substantial capital requirements, and uncertainty of clinical trial outcomes. However, the potential impact of successful broad-spectrum antiviral treatments could revolutionize how healthcare systems respond to viral outbreaks and manage routine viral infections across global populations.
